优势价格
快速发货
品质保证
技术支持
400-920-2911 sales@csnpharm.cn
MDM2
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| CSN18271 | SJ-172550 | 431979-47-4 | SJ-172550 is a small molecule inhibitor of MDMX and competes for the wild type p53 peptide binding to MDMX with an EC50 of 5 μM. |
| CSN17676 | RO8994 | 1309684-94-3 | RO8994 is a highly potent and selective series of spiroindolinone small-molecule MDM2 inhibitor, with IC50 of 5 nM (HTRF binding assays) and 20 nM (MTT proliferation assays). |
| CSN15939 | RITA | 213261-59-7 | RITA induced both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks. It is MDM2-p53 interaction inhibitor and activates p53 expression. |
| CSN19741 | PK11195 | 85532-75-8 | PK11195 is a 2‑Phenylindolylglyoxylyldipeptide Murine Double Minute2 (MDM2)/Translocator Protein (TSPO)/Human Constitutive Androstane Receptor (hCAR) Inhibitor, and is potentially useful for the Treatment of Gliomas. |
| CSN17157 | Nutlin 3b | 675576-97-3 | Nutlin 3b is a MDM2/p53 antagonist or inhibitor with IC50 of 13.6 μM. |
| CSN17156 | Nutlin 3a | 675576-98-4 | Nutlin 3a is an improved MDM2-p53 interation antagonist thus acting as p53 (TP53) activator and stabilizer. It is a more potent diastereoisomer of Nutlin-3. |
| CSN12388 | Nutlin 3(Random Configuration) | 890090-75-2 | Nutlin 3(Random Configuration) is an MDM2 antagonist which can activate p53 pathway through inhibition of p53-MDM2 interaction. |
| CSN18807 | Nutlin 3 | 548472-68-0 | Nutlin 3 is an MDM2 antagonist which can activate p53 pathway through inhibition of p53-MDM2 interaction. |
| CSN20477 | NSC 66811 | 6964-62-1 | NSC 66811 is a potent MDM2 inhibitor with Ki value of 120 nM which can disrupt MDM2-p53 interaction and activate p53 function. |
| CSN26552 | MA242 TFA | 1049704-18-8 | MA242 is a Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. MA242 decreased cell proliferation and induced apoptosis in pancreatic cancer cell lines regardless of p53 status. MA242 alone or in combination with gemcitabine inhibited pancreatic tumor growth and metastasis without any host toxicity. Our data indicate that targeting both MDM2 and NFAT1 represents a novel and effective strategy to treat pancreatic cancer. |
